Rituximab Biosimilar, Human CD20 mAb
Item Information
Catalog #
Size
Price
Description
Rituximab is a humanized IgG1-kappa monoclonal antibody specific for human CD20, expressed by B cells. Rituximab binding to CD20 results in B cell elimination by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab is used for B cell lymphomas/leukemias, for autoimmune disorders and in transplantation.
Product Overview
Isotype
IgG1 kappa
Source
Produced in the CHO stable cell line.
Formulation
0.2-uM filtered solution, pH 6.5, no stabilizers or preservatives
Purity
>95% by SDS-PAGE under reducing conditions and HPLC
Endotoxin
<1 EU/mg (LAL method)
Specificity/Sensitivity
Binds to human CD20.
Storage
4°C if used within 1 month, -20°C otherwise
Shipping Information
Shipped with an ice pack.
Application
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and assays for studying the biological pathways affected by Rituximab.
For Research Use Only. Not for use in diagnostic procedures.